Compare Crescent Energy Company Class A Common Stock (CRGY) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crescent Energy Company Class A Common Stock vs Ginkgo Bioworks Holdings Inc — how do they compare? Crescent Energy Company Class A Common Stock trades at $12.8 (market cap $4.30B), while Ginkgo Bioworks Holdings Inc trades at $13.16 (market cap $763.64M). The key difference: Crescent Energy Company Class A Common Stock is far larger — about 5.6× Ginkgo Bioworks Holdings Inc's market cap, and Crescent Energy Company Class A Common Stock pays a 3.69% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crescent Energy Company Class A Common Stock for 0 Days and Ginkgo Bioworks Holdings Inc for 7 Days on average.
| CRGY | DNA | |
|---|---|---|
Market Cap | $4.30B | $763.64M |
Volume | 15,201,625 | 3,204,177 |
Sector | Energy | Health |
52-Week High | $15.37 | $15.83 |
52-Week Low | $7.75 | $5.48 |
Typical Hold Time | 0 Days | 7 Days |
Enterprise Value | $9.31B | $865.59M |
Dividend Yield | 3.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.
Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crescent Energy Company Class A Common Stock
Crescent Energy acquires, develops, and produces oil and natural gas from onshore U.S. basins. Its portfolio includes producing assets with oil and natural gas exposure.
Read more on CRGY →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
